Rational modification of the lead molecule: Enhancement in the anticancer and dihydrofolate reductase inhibitory activity

Rational modification of the lead molecule: Enhancement in the anticancer and dihydrofolate reductase inhibitory activity Mechanism Inspired Development of Rationally Designed Dihydrofolate Reductase Inhibitors as Anticancer Agents Structural tuning of acridones for developing anticancer agents targeting dihydrofolate reductase Oxindole-Based Inhibitors of Cyclin-Dependent Kinase 2 (CDK2):  Design, Synthesis, Enzymatic Activities, and X-ray Crystallographic Analysis Design, synthesis, docking studies and biological evaluation of novel dihydro-1,3,5-triazines as human DHFR inhibitors A 2.13 Å Structure of E. coli Dihydrofolate Reductase Bound to a Novel Competitive Inhibitor Reveals a New Binding Surface Involving the M20 Loop Region High-Affinity Inhibitors of Dihydrofolate Reductase:  Antimicrobial and Anticancer Activities of 7,8-Dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with Small Molecular Size Structural Studies on Bioactive Compounds. 39. Biological Consequences of the Structural Modification of DHFR-Inhibitory 2,4-Diamino-6-(4-substituted benzylamino-3-nitrophenyl)-6-ethylpyrimidines (‘benzoprims') Receptor-based design of novel dihydrofolate reductase inhibitors: benzimidazole and indole derivatives Lead modification: Amino acid appended indoles as highly effective 5-LOX inhibitors